Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Genenta Science S.p.A. Unsponsored ADR (GNTA : NSDQ)

• Company Description    Genenta Science S.p.A. is a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for solid tumors, including the lead product candidate, Temferon(TM). Genenta Science S.p.A. is based in MILAN, Italy. Number of Employees: 13

• Price / Volume Information    Yesterday's Closing Price: $3.05 Daily Weekly Monthly 20 Day Moving Average: 9,738 shares Shares Outstanding: 18.29 (millions) Market Capitalization: $55.69 (millions) Beta: 0.59 52 Week High: $7.28 52 Week Low: $2.79 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -32.18% -35.12% 12 Week -12.75% -28.82% Year To Date -30.00% -33.65%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL OLGETTINA NO. 58 - MILAN,L6 20132 ITA ph: 39-02-2643-6639 fax: - investors@genenta.com http://www.genenta.com

• General Corporate Information    Officers Pierluigi Paracchi - Chief Executive Officer and Chairman Richard B. Slansky - Chief Financial Officer Todd Michael Wider - Director John Louis Cantello - Director Lauren Haeyong Chung - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 36870W100 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: - Next Expected EPS Date: - Share - Related Items Shares Outstanding: 18.29 Most Recent Split Date: (:1) Beta: 0.59 Market Capitalization: $55.69 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: -

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.12 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - - ROA 06/30/25 - - 03/31/25 - - 12/31/24 - - Current Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - 6.89 Quick Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - 6.89 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - - 12/31/24 - 0.74 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - 0.00

Powered by Zacks Investment Research ©